Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

A technology of myxoma virus and chronic infection, which is applied in the field of myxoma virus treatment, and can solve the problems of difficult virus shutdown and difficult genetic manipulation

Inactive Publication Date: 2008-04-09
THE JOHN P ROBARTS RES INST
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, VSV suffers from the same problems as reoviruses: genetic manipulation is difficult, and viral replication cannot be easily shut down

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
  • Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
  • Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0117] virus strain

[0118] Virus strains used included wild-type MVs, MVs modified to express green fluorescent protein ("GFP") or beta-galactosidase ("LacZ"), and killed ("dead") MVs. Viruses are prepared and titrated using standard techniques.

[0119] cell line

[0120] Mouse experiments were performed using mouse embryonic fibroblasts ("MEFs") derived from wild-type mice and mice with the following knockouts: IFNα / β receptor homozygous knockout, STAT1 Homozygous knockout, PKR heterozygous knockout, RNase L heterozygous knockout, Mx1 heterozygous knockout, PKR / RNase L / Mx1 triple homozygous knockout.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.

Description

technical field [0001] The present invention generally relates to the use of myxoma virus in therapy. Background technique [0002] Current treatments for various cancers often work by poisoning or killing cancer cells. Unfortunately, treatments that are toxic to cancer cells are generally toxic to healthy cells as well. Moreover, one of the main reasons for the effective treatment of cancer - the heterogeneity of tumors - is not well understood. Current mainstream therapies such as chemotherapy and radiation tend to be used within a narrow therapeutic spectrum of toxicity. Due to the diversity of tumor cells and the limited range of applications of these treatments, these types of treatments are not considered to be powerful tools. [0003] Modern anticancer therapies currently under development attempt to selectively target tumor cells, while being less toxic to healthy cells and thus more likely to leave healthy cells unaffected. [0004] Oncolytic therapy aims to use...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/275A61P35/00A61P31/12
Inventor 格兰特·麦克菲登约翰·C·贝尔
Owner THE JOHN P ROBARTS RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com